M&A - ABEONA THERAPEUTICS INC.

Form Type: 8-K

Filing Date: 2025-07-02

Corporate Action: Acquisition

Type: New

Accession Number: 000164117225017460

Filing Summary: On June 27, 2025, Abeona Therapeutics Inc. completed the previously disclosed sale of its Rare Pediatric Disease Priority Review Voucher (PRV). The company was awarded this voucher on April 28, 2025, under a U.S. FDA program designed to encourage the development of applications for rare pediatric diseases. The PRV was obtained following the approval of the company’s biologics license application for ZEVASKYN™. The Asset Sale was executed under an asset purchase agreement dated May 9, 2025, with gross proceeds of $155 million received from the purchaser at the close of the transaction. On July 2, 2025, the company announced it held approximately $225 million in cash and cash equivalents, including net proceeds from the Asset Sale, as of June 30, 2025. This information is preliminary and based on management estimates for the quarter, pending the completion of financial closing procedures.